The Menarini Group
http://www.menarini.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From The Menarini Group
Guardant’s FDA Approval For Colorectal Cancer Blood Test, Paves Road To Potential Medicare Coverage
On 29 July, Guardant Health Inc. announced it received US FDA approval for its blood test Shield to be used as a primary screening option for colorectal cancer, bringing it one step closer to gaining Medicare coverage.
News We’re Watching: Panel Backs Guardant Shield, EU Adopts AI Act, Magellan Settles Lead Test Claims
This week, an FDA advisory panel recommended approval of the Guardant Shield blood test for colon and rectal cancers; the EU Council signed off on the world’s first AI law; and the FDA challenged innovators to develop AI/ML technologies to detect gait freezing in individuals with Parkinson’s disease
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.
Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy
Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.
Company Information
- Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Glucose Testing
- Hematology, Coagulation
- Urine-based Testing
- Other Names / Subsidiaries
-
- A. Menarini Diagnostics S.r.l.
- Berlin Chemie AG
- Invida Group Private Limited
- Lusofarmaco
- Menarini Asia-Pacific Holdings (Menarini AP)
- VaxYnethic
- Stemline Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice